Of note, some researchers also showed that radiomic features had a great potential in predicting the clinical outcomes of NSCLC patients with sensitive EGFR mutation (19del/L858R) receiving first- or second-generation EGFR-TKIs as first-line targeted therapy (12–14). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.